Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT07136103
PHASE1

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Immunogenicity of ABBV-277 in Healthy Adult Participants

Sponsor: AbbVie

View on ClinicalTrials.gov

Summary

The objective of this study is to evaluate the safety, tolerability, immunogenicity and pharmacokinetics (PK ) properties following a single dose of ABBV-277 in healthy adult participants.

Official title: A First-in-Human Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Immunogenicity of ABBV-277 in Healthy Adult Subjects

Key Details

Gender

All

Age Range

18 Years - 65 Years

Study Type

INTERVENTIONAL

Enrollment

40

Start Date

2025-08-19

Completion Date

2026-05

Last Updated

2025-09-02

Healthy Volunteers

Yes

Interventions

DRUG

ABBV-277

• Intravenous (IV) infusion

DRUG

Placebo

• Intravenous (IV) infusion

Locations (1)

Acpru /Id# 265681

Grayslake, Illinois, United States